NEWS
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
NKGen Biotech presented new positive data on its SNK01 therapy for Alzheimer's disease at the 2024 AAIC.
The study showed that SNK01, a cryopreserved autologous non-genetically modified NK cell product, can effectively reduce α-synuclein (α-syn) protein levels in the cerebrospinal fluid of Alzheimer's patients. This is significant as increased α-syn correlates with worse cognitive performance and is not targeted by current treatments.
Key findings include:
-60% of patients showed decreased CSF α-syn levels
▪️90% of patients demonstrated stable or improved cognitive function
▪️SNK01 also improved amyloid, tau, and neuroinflammatory markers
▪️The therapy was well-tolerated with no treatment-related adverse events
NKGen plans to expand investigation in a larger Phase II trial with higher doses and longer treatment duration.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1397Followers
79Following
10KVisitors
Follow
RideTheTide : Is this a good news?
Jaguar8 OP RideTheTide : It is